Arcoxia GI Benefit Does Not Outweigh CV Risk, Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Drugs Advisory Committee votes 20-1 against recommending approval of Merck’s Vioxx follow-on etoricoxib.
You may also be interested in...
FDA Cold-Cox Merck; Arcoxia “Not Approvable” For Osteoarthritis
Agency indicates more data is needed on benefit-to-risk profile of the COX-2 inhibitor, but Merck is mum on whether it will continue to pursue approval.
FDA Cold-Cox Merck; Arcoxia “Not Approvable” For Osteoarthritis
Agency indicates more data is needed on benefit-to-risk profile of the COX-2 inhibitor, but Merck is mum on whether it will continue to pursue approval.
Merck Not Giving Up On Arcoxia U.S. Approval - Yet
CEO Clark says Merck continues to believe that the Vioxx follow-on could be “a valuable treatment” option for patients.